159 related articles for article (PubMed ID: 22152181)
1. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire.
Gold DT; Horne R; Coon CD; Price MA; Borenstein J; Varon SF; Satram-Hoang S; Macarios D
Value Health; 2011 Dec; 14(8):1109-16. PubMed ID: 22152181
[TBL] [Abstract][Full Text] [Related]
2. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
[TBL] [Abstract][Full Text] [Related]
3. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
Kendler DL; Bessette L; Hill CD; Gold DT; Horne R; Varon SF; Borenstein J; Wang H; Man HS; Wagman RB; Siddhanti S; Macarios D; Bone HG
Osteoporos Int; 2010 May; 21(5):837-46. PubMed ID: 19657689
[TBL] [Abstract][Full Text] [Related]
4. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
5. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women.
Flood EM; Beusterien KM; Green H; Shikiar R; Baran RW; Amonkar MM; Cella D
Health Qual Life Outcomes; 2006 Jul; 4():42. PubMed ID: 16834773
[TBL] [Abstract][Full Text] [Related]
6. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the osteoporosis patient satisfaction questionnaire (OPSQ).
Lai PS; Chua SS; Chan SP; Low WY; Wong IC
Maturitas; 2010 Jan; 65(1):55-63. PubMed ID: 19962839
[TBL] [Abstract][Full Text] [Related]
8. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
9. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.
Kendler DL; Macarios D; Lillestol MJ; Moffett A; Satram-Hoang S; Huang J; Kaur P; Tang ET; Wagman RB; Horne R
Menopause; 2014 Jan; 21(1):25-32. PubMed ID: 23676636
[TBL] [Abstract][Full Text] [Related]
10. Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates.
Reynolds K; Viswanathan HN; O'Malley CD; Muntner P; Harrison TN; Cheetham TC; Hsu JW; Gold DT; Silverman S; Grauer A; Morisky DE
Ann Pharmacother; 2012 May; 46(5):659-70. PubMed ID: 22510666
[TBL] [Abstract][Full Text] [Related]
11. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
12. Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study.
Oh KW; Kim DY; Lee YS; Kang MI;
J Bone Miner Metab; 2012 May; 30(3):359-66. PubMed ID: 22083905
[TBL] [Abstract][Full Text] [Related]
13. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
15. Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection.
Tatlock S; Arbuckle R; Sanchez R; Grant L; Khan I; Manvelian G; Spertus JA
Value Health; 2017 Mar; 20(3):430-440. PubMed ID: 28292488
[TBL] [Abstract][Full Text] [Related]
16. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
[TBL] [Abstract][Full Text] [Related]
17. Trust in Nurses Scale: construct validity and internal reliability evaluation.
Radwin LE; Cabral HJ
J Adv Nurs; 2010 Mar; 66(3):683-9. PubMed ID: 20423403
[TBL] [Abstract][Full Text] [Related]
18. Development of a psychometric scale to assess satisfaction with dental care among Sri Lankans.
Perera IR; Usgodaarachchi US
Community Dent Health; 2009 Sep; 26(3):150-6. PubMed ID: 19780355
[TBL] [Abstract][Full Text] [Related]
19. Denosumab for postmenopausal osteoporosis?
Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
[TBL] [Abstract][Full Text] [Related]
20. The effect of mandatory generic substitution on the safety of alendronate and patients' adherence.
Lai PS; Chua SS; Chong YH; Chan SP
Curr Med Res Opin; 2012 Aug; 28(8):1347-55. PubMed ID: 22746354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
